{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:18:35Z","timestamp":1793330315693,"version":"4.5.0"},"reference-count":119,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/nrrheum.2018.42","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T01:34:16Z","timestamp":1522287256000},"page":"279-289","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":162,"title":["Treatment in myositis"],"prefix":"10.1038","volume":"14","author":[{"given":"Chester V.","family":"Oddis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,29]]},"reference":[{"key":"BFnrrheum201842_CR1","doi-asserted-by":"publisher","unstructured":"Rider, L. G. et al. Update on outcome assessment in myositis. Nat. Rev. Rheumatol. https:\/\/doi.org\/10.1038\/nrrheum.2018.33 (2018).","DOI":"10.1038\/nrrheum.2018.33"},{"key":"BFnrrheum201842_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/mus.20649","volume":"35","author":"SA Greenberg","year":"2007","unstructured":"Greenberg, S. A. et al. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 35, 17\u201323 (2007).","journal-title":"Muscle Nerve"},{"key":"BFnrrheum201842_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg, S. A. et al. Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 57, 664\u2013678 (2005).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum201842_CR4","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1002\/art.24936","volume":"60","author":"H Bilgic","year":"2009","unstructured":"Bilgic, H. et al. Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum. 60, 3436\u20133446 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1046\/j.1365-2249.2002.01933.x","volume":"129","author":"K Kurasawa","year":"2002","unstructured":"Kurasawa, K. et al. Activation of pulmonary T cells in corticosteroid-resistant and -sensitive interstitial pneumonitis in dermatomyositis\/polymyositis. Clin. Exp. Immunol. 129, 541\u2013548 (2002).","journal-title":"Clin. Exp. Immunol."},{"key":"BFnrrheum201842_CR6","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00296-001-0146-y","volume":"21","author":"I Yamadori","year":"2001","unstructured":"Yamadori, I. et al. Lymphocyte subsets in lung tissues of interstitial pneumonia associated with untreated polymyositis\/dermatomyositis. Rheumatol. Int. 21, 89\u201393 (2001).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum201842_CR7","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3109\/s10165-008-0090-8","volume":"18","author":"A Katagiri","year":"2008","unstructured":"Katagiri, A. et al. Decrease in CD4+CD25+ and CD8+CD28+ T cells in interstitial pneumonitis associated with rheumatic disease. Mod. Rheumatol. 18, 562\u2013569 (2008).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum201842_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.4081\/reumatismo.2014.746","volume":"66","author":"A Notarnicola","year":"2014","unstructured":"Notarnicola, A. et al. Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies. Reumatismo 66, 215\u2013223 (2014).","journal-title":"Reumatismo"},{"key":"BFnrrheum201842_CR9","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/03009742.2010.517215","volume":"40","author":"H Shen","year":"2011","unstructured":"Shen, H. et al. Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand. J. Rheumatol. 40, 217\u2013220 (2011).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum201842_CR10","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/art.27465","volume":"62","author":"A Tournadre","year":"2010","unstructured":"Tournadre, A., Lenief, V. & Miossec, P. Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines. Arthritis Rheum. 62, 2144\u20132151 (2010).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/00002281-200111000-00002","volume":"13","author":"K Nagaraju","year":"2001","unstructured":"Nagaraju, K. Update on immunopathogenesis in inflammatory myopathies. Curr. Opin. Rheumatol. 13, 461\u2013468 (2001).","journal-title":"Curr. Opin. Rheumatol."},{"key":"BFnrrheum201842_CR12","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0002-9440(10)62513-8","volume":"159","author":"P Englund","year":"2001","unstructured":"Englund, P. et al. Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies. Am. J. Pathol. 159, 1263\u20131273 (2001).","journal-title":"Am. J. Pathol."},{"key":"BFnrrheum201842_CR13","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1002\/art.21103","volume":"52","author":"K Nagaraju","year":"2005","unstructured":"Nagaraju, K. et al. Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 52, 1824\u20131835 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR14","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2014-207172","volume":"74","author":"AP Lightfoot","year":"2015","unstructured":"Lightfoot, A. P. et al. In the idiopathic inflammatory myopathies (IIM), do reactive oxygen species (ROS) contribute to muscle weakness? Ann. Rheum. Dis. 74, 1340\u20131346 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201842_CR15","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1100\/tsw.2010.173","volume":"10","author":"A Catania","year":"2010","unstructured":"Catania, A. et al. The melanocortin system in control of inflammation. ScientificWorldJournal 10, 1840\u20131853 (2010).","journal-title":"ScientificWorldJournal"},{"key":"BFnrrheum201842_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2147\/DDDT.S33110","volume":"6","author":"T Levine","year":"2012","unstructured":"Levine, T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series. Drug Des. Devel. Ther. 6, 133\u2013139 (2012).","journal-title":"Drug Des. Devel. Ther."},{"key":"BFnrrheum201842_CR17","first-page":"9068061","volume":"2016","author":"A Patel","year":"2016","unstructured":"Patel, A., Seely, G. & Aggarwal, R. Repository corticotropin injection for treatment of idiopathic inflammatory myopathies. Case Rep. Rheumatol. 2016, 9068061 (2016).","journal-title":"Case Rep. Rheumatol."},{"key":"BFnrrheum201842_CR18","doi-asserted-by":"publisher","unstructured":"Aggarwal, R. et al. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann. Rheum. Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212047 (2017).","DOI":"10.1136\/annrheumdis-2017-212047"},{"key":"BFnrrheum201842_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe, M. M. et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am. J. Med. 94, 379\u2013387 (1993).","journal-title":"Am. J. Med."},{"key":"BFnrrheum201842_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00124743-199504000-00007","volume":"1","author":"ED Newman","year":"1995","unstructured":"Newman, E. D. & Scott, D. W. The use of low-dose methotrexate in the treatment of pollymyositis and dermatomyositis. J. Clin. Rheumatol 1, 99\u2013102 (1995).","journal-title":"J. Clin. Rheumatol"},{"key":"BFnrrheum201842_CR21","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(15)01021-1","volume":"387","author":"N Ruperto","year":"2016","unstructured":"Ruperto, N. et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet 387, 671\u2013678 (2016).","journal-title":"Lancet"},{"key":"BFnrrheum201842_CR22","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00651040 (2016)."},{"key":"BFnrrheum201842_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0002-9343(93)90148-I","volume":"94","author":"MM Joffe","year":"1993","unstructured":"Joffe, M. M. et al. Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azaathioprine, and methotrexate and a comparison of their efficacy. Am. J. Med. 94, 379\u2013387 (1993).","journal-title":"Am. J. Med."},{"key":"BFnrrheum201842_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/art.1780240107","volume":"24","author":"TW Bunch","year":"1981","unstructured":"Bunch, T. W. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 24, 45\u201348 (1981).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.7326\/0003-4819-92-3-365","volume":"92","author":"TW Bunch","year":"1980","unstructured":"Bunch, T. W. et al. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann. Intern. Med. 92, 365\u2013369 (1980).","journal-title":"Ann. Intern. Med."},{"key":"BFnrrheum201842_CR26","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/1529-0131(199803)41:3<392::AID-ART3>3.0.CO;2-X","volume":"41","author":"L Villalba","year":"1998","unstructured":"Villalba, L. et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 41, 392\u2013399 (1998).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/rheumatology\/keh499","volume":"44","author":"V Majithia","year":"2005","unstructured":"Majithia, V. & Harisdangkul, V. Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology 44, 386\u2013389 (2005).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR28","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/rheumatology\/kel336","volume":"46","author":"CN Pisoni","year":"2007","unstructured":"Pisoni, C. N. et al. Mycophenolate mofetil treatment in resistant myositis. Rheumatology 46, 516\u2013518 (2007).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR29","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.wnl.0000208416.32471.c0","volume":"66","author":"J Rowin","year":"2006","unstructured":"Rowin, J. et al. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 66, 1245\u20131247 (2006).","journal-title":"Neurology"},{"key":"BFnrrheum201842_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/mus.10026","volume":"25","author":"C Schneider","year":"2002","unstructured":"Schneider, C. et al. Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome. Muscle Nerve 25, 286\u2013288 (2002).","journal-title":"Muscle Nerve"},{"key":"BFnrrheum201842_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.autrev.2009.04.003","volume":"9","author":"MG Danieli","year":"2009","unstructured":"Danieli, M. G. et al. Intravenous immunoglobulin as add on treatment with mycophenolate mofetil in severe myositis. Autoimmun. Rev. 9, 124\u2013127 (2009).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201842_CR32","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(99)01927-3","volume":"353","author":"CV Oddis","year":"1999","unstructured":"Oddis, C. V. et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353, 1762\u20131763 (1999).","journal-title":"Lancet"},{"key":"BFnrrheum201842_CR33","first-page":"188","volume":"111","author":"T Mitsui","year":"2011","unstructured":"Mitsui, T. et al. The effects of FK506 on refractory inflammatory myopathies. Acta Neurol. Belg. 111, 188\u2013194 (2011).","journal-title":"Acta Neurol. Belg."},{"key":"BFnrrheum201842_CR34","first-page":"1369","volume":"32","author":"O Lambotte","year":"2005","unstructured":"Lambotte, O. et al. Efficacy of rituximab in refractory polymyositis. J. Rheumatol 32, 1369\u20131370 (2005).","journal-title":"J. Rheumatol"},{"key":"BFnrrheum201842_CR35","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1002\/art.20849","volume":"52","author":"TD Levine","year":"2005","unstructured":"Levine, T. D. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 52, 601\u2013607 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR36","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/rheumatology\/ker088","volume":"50","author":"EA Mahler","year":"2011","unstructured":"Mahler, E. A. et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology 50, 2206\u20132213 (2011).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR37","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1002\/acr.20219","volume":"62","author":"R Valiyil","year":"2010","unstructured":"Valiyil, R. et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 62, 1328\u20131334 (2010).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201842_CR38","first-page":"1864","volume":"34","author":"CC Mok","year":"2007","unstructured":"Mok, C. C., Ho, L. Y. & To, C. H. Rituximab for refractory polymyositis: an open-label prospective study. J. Rheumatol. 34, 1864\u20131868 (2007).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201842_CR39","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1001\/archderm.143.6.763","volume":"143","author":"L Chung","year":"2007","unstructured":"Chung, L., Genovese, M. C. & Fiorentino, D. F. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch. Dermatol. 143, 763\u2013767 (2007).","journal-title":"Arch. Dermatol."},{"key":"BFnrrheum201842_CR40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1002\/art.37754","volume":"65","author":"CV Oddis","year":"2013","unstructured":"Oddis, C. V. et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 65, 314\u2013324 (2013).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR41","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/art.20349","volume":"50","author":"LG Rider","year":"2004","unstructured":"Rider, L. G. et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 50, 2281\u20132290 (2004).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR42","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/art.38270","volume":"66","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal, R. et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 66, 740\u2013749 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201842_CR43","first-page":"1802","volume":"33","author":"F Iannone","year":"2006","unstructured":"Iannone, F. et al. Use of etanercept in the treatment of dermatomyositis: a case series. J. Rheumatol. 33, 1802\u20131804 (2006).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201842_CR44","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/ana.22477","volume":"70","author":"G Muscle Study","year":"2011","unstructured":"Muscle Study, G. A randomized, pilot trial of etanercept in dermatomyositis. Ann. Neurol. 70, 427\u2013436 (2011).","journal-title":"Ann. Neurol."},{"key":"BFnrrheum201842_CR45","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1093\/rheumatology\/keh539","volume":"44","author":"A Anandacoomarasamy","year":"2005","unstructured":"Anandacoomarasamy, A., Howe, G. & Manolios, N. Advanced refractory polymyositis responding to infliximab. Rheumatology 44, 562\u2013563 (2005).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR46","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1136\/ard.2005.048744","volume":"65","author":"P Efthimiou","year":"2006","unstructured":"Efthimiou, P., Schwartzman, S. & Kagen, L. J. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann. Rheum. Dis. 65, 1233\u20131236 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201842_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1159\/000070852","volume":"50","author":"GJ Hengstman","year":"2003","unstructured":"Hengstman, G. J. et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur. Neurol. 50, 10\u201315 (2003).","journal-title":"Eur. Neurol."},{"key":"BFnrrheum201842_CR48","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1093\/rheumatology\/keh285","volume":"43","author":"A Selva-O'Callaghan","year":"2004","unstructured":"Selva-O'Callaghan, A. et al. Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. Rheumatology 43, 1196\u20131197 (2004).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000079547","volume":"52","author":"GJ Hengstman","year":"2004","unstructured":"Hengstman, G. J., F. H. van den Hoogen & van Engelen, B. G. Treatment of dermatomyositis and polymyositis with anti-tumor necrosis factor-alpha: long-term follow-up. Eur. Neurol. 52, 61\u201363 (2004).","journal-title":"Eur. Neurol."},{"key":"BFnrrheum201842_CR50","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1136\/ard.2007.077974","volume":"67","author":"M Dastmalchi","year":"2008","unstructured":"Dastmalchi, M. et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann. Rheum. Dis. 67, 1670\u20131677 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201842_CR51","doi-asserted-by":"publisher","unstructured":"Schiffenbauer, A. et al. A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis. Semin. Arthritis Rheum. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.10.010 (2017).","DOI":"10.1016\/j.semarthrit.2017.10.010"},{"key":"BFnrrheum201842_CR52","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10067-009-1370-1","volume":"29","author":"Y Ishikawa","year":"2010","unstructured":"Ishikawa, Y. et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin. Rheumatol. 29, 563\u2013566 (2010).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201842_CR53","first-page":"780","volume":"146","author":"R Klein","year":"2010","unstructured":"Klein, R. et al. Tumor necrosis factor inhibitor-associated dermatomyositis. Arch. Dermatol. 146, 780\u2013784 (2010).","journal-title":"Arch. Dermatol."},{"key":"BFnrrheum201842_CR54","first-page":"192","volume":"39","author":"G Riolo","year":"2012","unstructured":"Riolo, G. & Towheed, T. E. Anti-tumor necrosis factor inhibitor therapy-induced dermatomyositis and fasciitis. J. Rheumatol. 39, 192\u2013194 (2012).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201842_CR55","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1093\/rheumatology\/ken074","volume":"47","author":"P Riley","year":"2008","unstructured":"Riley, P. et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology 47, 877\u2013880 (2008).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR56","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/rheumatology\/ker152","volume":"50","author":"M Narazaki","year":"2011","unstructured":"Narazaki, M. et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology 50, 1344\u20131346 (2011).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR57","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/rheumatology\/keu234","volume":"53","author":"M Kondo","year":"2014","unstructured":"Kondo, M. et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? Rheumatology 53, 1907\u20131908 (2014).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR58","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02043548 (2017)."},{"key":"BFnrrheum201842_CR59","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1002\/art.40064","volume":"69","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal, R. et al. 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative initiative. Arthritis Rheumatol. 69, 898\u2013910 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201842_CR60","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","volume":"160","author":"B Arabshahi","year":"2012","unstructured":"Arabshahi, B. et al. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J. Pediatr. 160, 520\u2013522 (2012).","journal-title":"J. Pediatr."},{"key":"BFnrrheum201842_CR61","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10067-014-2507-4","volume":"34","author":"AM Kerola","year":"2015","unstructured":"Kerola, A. M. & Kauppi, M. J. Abatacept as a successful therapy for myositis-a case-based review. Clin. Rheumatol. 34, 609\u2013612 (2015).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201842_CR62","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/rheumatology\/ket251","volume":"53","author":"K Maeshima","year":"2014","unstructured":"Maeshima, K. et al. Successful treatment of refractory anti-signal recognition particle myopathy using abatacept. Rheumatology 53, 379\u2013380 (2014).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR63","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.jbspin.2011.03.022","volume":"78","author":"JL Musuruana","year":"2011","unstructured":"Musuruana, J. L. & Cavallasca, J. A. Abatacept for treatment of refractory polymyositis. Joint Bone Spine 78, 431\u2013432 (2011).","journal-title":"Joint Bone Spine"},{"key":"BFnrrheum201842_CR64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","volume":"77","author":"A Tjarnlund","year":"2018","unstructured":"Tjarnlund, A. et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann. Rheum. Dis. 77, 55\u201362 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201842_CR65","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02971683 (2018)."},{"key":"BFnrrheum201842_CR66","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1136\/annrheumdis-2012-202857","volume":"73","author":"M Zong","year":"2014","unstructured":"Zong, M. et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann. Rheum. Dis. 73, 913\u2013920 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201842_CR67","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1056\/NEJM199312303292704","volume":"329","author":"MC Dalakas","year":"1993","unstructured":"Dalakas, M. C. et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N. Engl. J. Med. 329, 1993\u20132000 (1993).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201842_CR68","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/art.10053","volume":"46","author":"P Cherin","year":"2002","unstructured":"Cherin, P. et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 46, 467\u2013474 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR69","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/s10165-011-0534-4","volume":"22","author":"N Miyasaka","year":"2012","unstructured":"Miyasaka, N. et al. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod. Rheumatol. 22, 382\u2013393 (2012).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum201842_CR70","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02728752 (2018)."},{"key":"BFnrrheum201842_CR71","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.autrev.2010.09.004","volume":"10","author":"MG Danieli","year":"2011","unstructured":"Danieli, M. G. et al. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun. Rev. 10, 144\u2013149 (2011).","journal-title":"Autoimmun. Rev."},{"key":"BFnrrheum201842_CR72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1111\/joim.12481","volume":"280","author":"H Alexanderson","year":"2016","unstructured":"Alexanderson, H. Physical exercise as a treatment for adult and juvenile myositis. J. Intern. Med. 280, 75\u201396 (2016).","journal-title":"J. Intern. Med."},{"key":"BFnrrheum201842_CR73","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1093\/rheumatology\/37.2.196","volume":"37","author":"GF Wiesinger","year":"1998","unstructured":"Wiesinger, G. F. et al. Improvement of physical fitness and muscle strength in polymyositis\/dermatomyositis patients by a training programme. Br. J. Rheumatol. 37, 196\u2013200 (1998).","journal-title":"Br. J. Rheumatol."},{"key":"BFnrrheum201842_CR74","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/rheumatology\/38.7.608","volume":"38","author":"H Alexanderson","year":"1999","unstructured":"Alexanderson, H., Stenstrom, C. H. & Lundberg, I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology 38, 608\u2013611 (1999).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR75","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/030097400447679","volume":"29","author":"H Alexanderson","year":"2000","unstructured":"Alexanderson, H. et al. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand. J. Rheumatol. 29, 295\u2013301 (2000).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum201842_CR76","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/art.39624","volume":"68","author":"LA Munters","year":"2016","unstructured":"Munters, L. A. et al. Endurance exercise improves molecular pathways of aerobic metabolism in patients with myositis. Arthritis Rheumatol. 68, 1738\u20131750 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201842_CR77","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen, A. L. et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 63, 713\u2013721 (2011).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR78","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMc1506163","volume":"373","author":"AL Mammen","year":"2015","unstructured":"Mammen, A. L. & Tiniakou, E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N. Engl. J. Med. 373, 1680\u20131682 (2015).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201842_CR79","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/acr.20212","volume":"62","author":"PA Morganroth","year":"2010","unstructured":"Morganroth, P. A., Kreider, M. E. & Werth, V. P. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 62, 1496\u20131501 (2010).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201842_CR80","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","volume":"107","author":"IC Mira-Avendano","year":"2013","unstructured":"Mira-Avendano, I. C. et al. A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis. Respir. Med. 107, 890\u2013896 (2013).","journal-title":"Respir. Med."},{"key":"BFnrrheum201842_CR81","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.121043","volume":"40","author":"A Fischer","year":"2013","unstructured":"Fischer, A. et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J. Rheumatol. 40, 640\u2013646 (2013).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201842_CR82","doi-asserted-by":"publisher","first-page":"694","DOI":"10.3109\/14397595.2013.874762","volume":"24","author":"H Tsuchiya","year":"2014","unstructured":"Tsuchiya, H. et al. Mycophenolate mofetil therapy for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis. Mod. Rheumatol. 24, 694\u2013696 (2014).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum201842_CR83","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1164\/ajrccm.164.7.2103110","volume":"164","author":"WW Douglas","year":"2001","unstructured":"Douglas, W. W. et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Ann. J. Respir. Crit. Care Med. 164, 1182\u20131185 (2001).","journal-title":"Ann. J. Respir. Crit. Care Med."},{"key":"BFnrrheum201842_CR84","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/art.10794","volume":"47","author":"I Marie","year":"2002","unstructured":"Marie, I. et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum. 47, 614\u2013622 (2002).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR85","first-page":"1719","volume":"32","author":"H Kameda","year":"2005","unstructured":"Kameda, H. et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute\/subacute interstitial pneumonia in patients with dermatomyositis. J. Rheumatol. 32, 1719\u20131726 (2005).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201842_CR86","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/03009740310002542","volume":"32","author":"CC Mok","year":"2003","unstructured":"Mok, C. C., To, C. H. & Szeto, M. L. Successful treatment of dermatomyositis-related rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand. J. Rheumatol. 32, 181\u2013183 (2003).","journal-title":"Scand. J. Rheumatol."},{"key":"BFnrrheum201842_CR87","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/rheumatology\/kel112","volume":"46","author":"Y Yamasaki","year":"2007","unstructured":"Yamasaki, Y. et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis\/dermatomyositis. Rheumatology 46, 124\u2013130 (2007).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR88","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1053\/sarh.2002.50012","volume":"32","author":"A Schnabel","year":"2003","unstructured":"Schnabel, A. et al. Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. Semin. Arthritis Rheum. 32, 273\u2013284 (2003).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum201842_CR89","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1378\/chest.10-0360","volume":"139","author":"CJ Bakewell","year":"2011","unstructured":"Bakewell, C. J. & Raghu, G. Polymyositis associated with severe interstitial lung disease: remission after three doses of IV immunoglobulin. Chest 139, 441\u2013443 (2011).","journal-title":"Chest"},{"key":"BFnrrheum201842_CR90","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s00408-009-9146-6","volume":"187","author":"Y Suzuki","year":"2009","unstructured":"Suzuki, Y. et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis\/dermatomyositis. Lung 187, 201\u2013206 (2009).","journal-title":"Lung"},{"key":"BFnrrheum201842_CR91","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s10067-011-1713-6","volume":"30","author":"T Kotani","year":"2011","unstructured":"Kotani, T. et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute\/subacute interstitial pneumonia. Clin. Rheumatol. 30, 1021\u20131028 (2011).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201842_CR92","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","volume":"36","author":"DJ Go","year":"2016","unstructured":"Go, D. J. et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol. Int. 36, 125\u2013131 (2016).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum201842_CR93","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1002\/art.21240","volume":"52","author":"MR Wilkes","year":"2005","unstructured":"Wilkes, M. R. et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 52, 2439\u20132446 (2005).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201842_CR94","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","volume":"54","author":"T Kurita","year":"2015","unstructured":"Kurita, T. et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology 54, 39\u201344 (2015).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR95","first-page":"707","volume":"23","author":"S Ochi","year":"2005","unstructured":"Ochi, S. et al. Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis\/dermatomyositis. Clin. Exp. Rheumatol. 23, 707\u2013710 (2005).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201842_CR96","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/08916930500124023","volume":"38","author":"K Takada","year":"2005","unstructured":"Takada, K., Nagasaka, K. & Miyasaka, N. Polymyositis\/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants. Autoimmunity 38, 383\u2013392 (2005).","journal-title":"Autoimmunity"},{"key":"BFnrrheum201842_CR97","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/resp.12214","volume":"19","author":"GJ Keir","year":"2014","unstructured":"Keir, G. J. et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 19, 353\u2013359 (2014).","journal-title":"Respirology"},{"key":"BFnrrheum201842_CR98","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","volume":"54","author":"H Andersson","year":"2015","unstructured":"Andersson, H. et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology 54, 1420\u20131428 (2015).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR99","doi-asserted-by":"publisher","first-page":"e0133702","DOI":"10.1371\/journal.pone.0133702","volume":"10","author":"Y Allenbach","year":"2015","unstructured":"Allenbach, Y. et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti-synthetase auto-antibodies: an open-label, phase II trial. PLoS ONE 10, e0133702 (2015).","journal-title":"PLoS ONE"},{"key":"BFnrrheum201842_CR100","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3899\/jrheum.150844","volume":"43","author":"J Bauhammer","year":"2016","unstructured":"Bauhammer, J. et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: Anti-Ro52 positivity as a marker for severity and treatment response. J. Rheumatol. 43, 1566\u20131574 (2016).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201842_CR101","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03215927 (2017)."},{"key":"BFnrrheum201842_CR102","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.38322","volume":"66","author":"R Conway","year":"2014","unstructured":"Conway, R. et al. Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheumatol. 66, 803\u2013812 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"BFnrrheum201842_CR103","doi-asserted-by":"publisher","first-page":"h1269","DOI":"10.1136\/bmj.h1269","volume":"350","author":"R Conway","year":"2015","unstructured":"Conway, R. et al. Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials. BMJ 350, h1269 (2015).","journal-title":"BMJ"},{"key":"BFnrrheum201842_CR104","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/0253-7613.201027","volume":"49","author":"SB Pai","year":"2017","unstructured":"Pai, S. B. et al. Hydroxychloroquine-induced erythroderma. Indian J. Pharmacol. 49, 132\u2013134 (2017).","journal-title":"Indian J. Pharmacol."},{"key":"BFnrrheum201842_CR105","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0190-9622(85)70108-9","volume":"12","author":"GA Slagel","year":"1985","unstructured":"Slagel, G. A. & James, W. D. Plaquenil-induced erythroderma. J. Am. Acad. Dermatol. 12, 857\u2013862 (1985).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum201842_CR106","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/archderm.142.1.65","volume":"142","author":"JC Edge","year":"2006","unstructured":"Edge, J. C. et al. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch. Dermatol. 142, 65\u201369 (2006).","journal-title":"Arch. Dermatol."},{"key":"BFnrrheum201842_CR107","first-page":"1542","volume":"27","author":"AC Gelber","year":"2000","unstructured":"Gelber, A. C., Nousari, H. C. & Wigley, F. M. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: a series of 4 cases. Rheumatol. J. 27, 1542\u20131545 (2000).","journal-title":"Rheumatol. J."},{"key":"BFnrrheum201842_CR108","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1093\/rheumatology\/kew396","volume":"56","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal, R. et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology 56, 247\u2013254 (2017).","journal-title":"Rheumatology"},{"key":"BFnrrheum201842_CR109","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","volume":"152","author":"DJ Kurtzman","year":"2016","unstructured":"Kurtzman, D. J. et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment. JAMA Dermatol. 152, 944\u2013945 (2016).","journal-title":"JAMA Dermatol."},{"key":"BFnrrheum201842_CR110","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.semarthrit.2016.08.009","volume":"46","author":"JJ Paik","year":"2017","unstructured":"Paik, J. J. & Christopher-Stine, L. A case of refractory dermatomyositis responsive to tofacitinib. Semin. Arthritis Rheum. 46, e19 (2017).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum201842_CR111","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1002\/acr.23210","volume":"69","author":"A Rogers","year":"2017","unstructured":"Rogers, A. et al. Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res. 69, 1909\u20131914 (2017).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201842_CR112","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3109\/14397595.2014.988197","volume":"25","author":"AC Tayfur","year":"2015","unstructured":"Tayfur, A. C. et al. Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis. Mod. Rheumatol. 25, 615\u2013620 (2015).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum201842_CR113","first-page":"408","volume":"32","author":"I Pagnini","year":"2014","unstructured":"Pagnini, I. et al. Sodium thiosulfate for the treatment of calcinosis secondary to juvenile dermatomyositis. Clin. Exp. Rheumatol. 32, 408\u2013409 (2014).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrrheum201842_CR114","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/j.jaad.2013.03.022","volume":"69","author":"GP Smith","year":"2013","unstructured":"Smith, G. P. Intradermal sodium thiosulfate for exophytic calcinosis cutis of connective tissue disease. J. Am. Acad. Dermatol. 69, e146\u2013147 (2013).","journal-title":"J. Am. Acad. Dermatol."},{"key":"BFnrrheum201842_CR115","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1002\/acr.20325","volume":"62","author":"I Marie","year":"2010","unstructured":"Marie, I. et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res. 62, 1748\u20131755 (2010).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201842_CR116","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","volume":"73","author":"BW Higgs","year":"2014","unstructured":"Higgs, B. W. et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann. Rheum. Dis. 73, 256\u2013262 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201842_CR117","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03002649 (2018)."},{"key":"BFnrrheum201842_CR118","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02612857 (2017)."},{"key":"BFnrrheum201842_CR119","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2217\/ijr.14.43","volume":"9","author":"S Moghadam-Kia","year":"2014","unstructured":"Moghadam-Kia, S., Oddis, C. V. & Aggarwal, R. Update on the treatment of myositis. Int. J. Clin. Rheumatol. 9, 505\u2013518 (2014).","journal-title":"Int. J. Clin. Rheumatol."}],"updated-by":[{"DOI":"10.1038\/s41584-018-0086-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000}}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.42","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/nrrheum.2018.42","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2018.42.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T08:15:38Z","timestamp":1719908138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2018.42"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,29]]},"references-count":119,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["BFnrrheum201842"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2018.42","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,29]]},"assertion":[{"value":"29 March 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the originally published version of this article, several references in Table 1 were incorrect. These errors have now been corrected in the HTML and PDF versions of the manuscript.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Both C.V.O. and R.A. receive clinical trial support from Genentech, Idera Pharmaceuticals, Bristol-Myers Squibb and Mallinckrodt.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}